Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can extra salt calm racing hearts? new POTS study aims to find out

NCT ID NCT05924646

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether eating more salt can help people with POTS, a condition that causes a fast heart rate and dizziness when standing. Researchers will compare a high-salt diet to a normal-salt diet over 3 months in 50 adults. The goal is to see if extra salt lowers heart rate and improves symptoms like lightheadedness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows: * Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing. * Absence of orthostatic hypotension (\>20/10 mmHg decrease) within 3 minutes standing. * Chronic orthostatic symptoms that improve with recumbence. * Age 18-60 years old. * Ability to attend the Calgary Autonomic Research Clinic in Calgary. * Resident of Canada Exclusion Criteria: * Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease) * Participants with somatization or severe anxiety symptoms will be excluded * Pregnant (self-reported) * Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest. * Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies * Fludrocortisone use (due to effects on renal Na+ handling) * Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postural orthostatic tachycardia syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 4Z6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.